PPLPHARMA

Piramal Pharma Ltd.

NSE: PPLPHARMA

BSE: 543635

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

226.62+7.0 (+3.17%)

8 Sep, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

28.4 / 100

Value Score

25.2 / 100

Price Momentum Score

89.0 / 100

QVM Score

40.6 / 100

Key Metrics

Market Cap

30068.90

P/E (TTM)

P/B

3.68

P/S (TTM)

3.27

EV/EBITDA

34.30

CAPE (5Y)

ROE (TTM)

-4.00

ROCE (TTM)

1.87

ROA (TTM)

-1.94

Avg 3Y ROE

-0.87

Earnings 3Y CAGR

-17.86

Sales 3Y CAGR

7.80

Sales 5Y CAGR

24.72

Debt/Equity

0.70

Consensus TP

232.50

Strong Buy %

60.00

Promoter Holding

34.80

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Piramal Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 89.0 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

89.0 / 100

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.7 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.1 in the last 1 year

What is Debt to Equity?

Negative

Stock is fairly expensive with negative EPS on a trailing 12-month basis

Earnings yield of -1.04% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis

What is Earnings yield (E/P)?

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -0.85% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Low and declining ROE

The company reported low ROE of -4.0% for 12-month ended 30 Jun 2026 and ROE declined by -513 bps from 1 year ago

What is ROE (FY)?

Low and declining operating margin

The company reported low operating margin of 1.66% for 12-month ended 30 Jun 2026 and operating margin declined by -401 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 0.78% for 12-month ended 30 Jun 2026 and the growth was 9.81 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 0.78

-99.6111701.8

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -426.86% for 12-month ended 30 Jun 2026 and the growth was 434.06 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 57.7 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

57.7 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Piramal Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Piramal Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Piramal Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	34.79	34.79	34.79	34.79	35.02	35.02	35.02	34.95	34.95	34.95	34.95	34.86	34.86	34.86	34.86	34.80
Indian Promoter	34.79	34.79	34.79	34.79	35.02	35.02	35.02	34.95	34.95	34.95	34.95	34.86	34.86	34.86	34.86	34.80
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	32.21	46.55	44.25	40.50	40.39	42.19	42.71	44.37	45.53	45.78	46.26	45.11	45.16	45.35	45.79	27.09
Mutual Funds / UTI	0.54	0.51	0.53	0.91	3.80	6.28	9.01	10.12	11.21	11.66	12.73	12.32	13.11	14.03	14.12	13.18
FI/Bank/Insurance	4.22	4.17	4.18	4.21	3.80	2.88	2.64	2.43	2.22	2.13	1.79	1.67	1.49	1.38	1.24	1.03
Govt	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	27.36	41.29	39.28	35.01	32.37	32.51	30.58	31.41	31.73	31.68	31.49	30.86	30.27	29.66	30.17	12.51
Other Institutions	0.09	0.58	0.27	0.36	0.41	0.52	0.47	0.40	0.37	0.30	0.26	0.26	0.29	0.28	0.25	0.36
Non-Institution	32.99	18.65	20.96	24.71	24.59	22.79	22.26	20.69	19.52	19.27	18.78	20.03	19.98	19.79	19.36	38.11
Bodies Corporate	1.38	2.67	3.48	3.09	2.15	1.83	1.87	1.48	1.25	1.23	1.20	1.27	1.16	1.30	1.12	1.14
Others (incl. Retail) No. of shareholders	31.61 1,78,290	15.98 2,28,188	17.48 2,39,625	21.62 2,75,571	22.44 2,98,892	20.96 2,90,629	20.39 2,96,405	19.21 3,04,865	18.27 3,58,264	18.04 4,16,786	17.58 4,31,318	18.76 4,56,843	18.82 4,60,880	18.49 4,52,219	18.24 4,49,143	36.97 4,59,534

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Smallcap 50	1.57%	33 / 49
2	Nifty Pharma	1.23%	20 / 20
3	Nifty Healthcare	1.06%	19 / 20
4	Nifty Smallcap 250	0.58%	46 / 249
5	Nifty 500	0.06%	259 / 499
6	Nifty Total Market	0.06%	276 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Piramal Pharma Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
East Bridge Capital Master Fund I Limited	31 Oct 2023	buy	₹ 102.80	3.36 cr	₹ 345.85 cr
East Bridge Capital Master Fund Limited	31 Oct 2023	sell	₹ 102.80	3.36 cr	₹ 345.85 cr
Ishares Core Emerging Markets Mauritius Co	03 Nov 2022	sell	₹ 166.95	40.51 lac	₹ 67.63 cr
Ishares Core Msci Emerging Markets Etf	03 Nov 2022	buy	₹ 166.95	40.51 lac	₹ 67.63 cr

Corporate Actions

History of Piramal Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 0.14/share
Record date: 16th Jul 2025Ex-date: 16th Jul 2025
Announced on: 14th May 2025
Dividend₹ 0.11/share
Record date: 12th Jul 2024Ex-date: 12th Jul 2024
Announced on: 10th May 2024
Rights Issue(5 new shares @ ₹81 for 46 existing shares)
Ex-date: 2nd Aug 2023Announced on: 28th Mar 2023
"Rights ISIN INE0DK520011 CINS Y6985K138 SEDOL BNG4DR4."

Company Profile

Overview of Piramal Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. I...

Key personnel

Mr. Peter Stevenson

Non-Executive Independent Director

Mr. Maneesh Sharma

Compliance Officer, Company Secretary

Ms. Nandini A. PiramalD

Executive Chairman of the Board

Mr. Vivek ValsarajD

Chief Financial Officer, Executive Director

Mr. Peter DeYoungD

Executive Director, Chief Executive Officer of Global Pharma

Mr. Amit JainD

Non-Executive Director

Ms. Nathalie LeitchD

Non-Executive Director

Mr. Sridhar GorthiD

Non-Executive Independent Director

View all

Incorporated on

04 Mar 2020

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

7,120

IPO date

19 Oct 2022

Free Float

60,25,00,436

Website

https://www.piramal.com/businesses/piramal-pharma/

Phone no.

+91223802300

Address

GR. FLR., PIRAMAL ANANTA, AGATSYA CORP. PARK,, KAMANI JUNCTION,, LBS MARG, KURLA,, , 400070, India

Frequently Asked Questions

What is the current share price of Piramal Pharma Ltd.?

The current share price of Piramal Pharma Ltd. is ₹ 226.62 as of 8 Sep 2026.

What is the market capitalisation of Piramal Pharma Ltd.?

The market capitalisation of Piramal Pharma Ltd. stands at ₹ 30,068.90 Cr.

What is the PE ratio of Piramal Pharma Ltd.?

The Price-to-Earnings (PE) ratio of Piramal Pharma Ltd. is - as of the latest trailing twelve months data.

What is the ROE and ROCE of Piramal Pharma Ltd.?

Piramal Pharma Ltd. has a Return on Equity (ROE) of -4.00% and a Return on Capital Employed (ROCE) of 1.87% as per the latest financial reports.

What is the 52-week high and low of Piramal Pharma Ltd.?

The 52-week high of Piramal Pharma Ltd. is - and the 52-week low is -.

What is the dividend yield of Piramal Pharma Ltd.?

The dividend yield of Piramal Pharma Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Piramal Pharma Ltd.?

Foreign Institutional Investors (FII) hold 12.51%, Domestic Institutional Investors (DII) hold 14.21% and retail/public investors hold 36.97% of Piramal Pharma Ltd. shares.

What sector does Piramal Pharma Ltd. belong to?

Piramal Pharma Ltd. operates in the Healthcare sector. 100% of analysts have a Buy or Strong Buy rating on Piramal Pharma Ltd. with a consensus target price of ₹ 232.50, implying 2.59% upside from current levels.

What is the beta of Piramal Pharma Ltd.?

The beta of Piramal Pharma Ltd. is 1.17, indicating its price volatility relative to the broader market. Over the past 1 year, Piramal Pharma Ltd. has delivered an absolute return of 21.34%.

What is the RSI of Piramal Pharma Ltd.?

The 14-day Relative Strength Index (RSI) of Piramal Pharma Ltd. is 70.50, placing it in the overbought zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Piramal Pharma Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Piramal Pharma Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Holdings and Presence

Stock Analysis

Corporate Actions

Company Profile